In 2011, Dr. Kayte Fischer and Dr. Adam Mendelsohn dedicated themselves full-time towards realizing Nano Precision Medical’s vision.
Dr. Lily Peng completed her M.D. and Ph.D. in 2012, and remains actively engaged with Nano Precision Medical in an advisory capacity.
After spending its early years within the QB3 incubator network, Nano Precision Medical moved into its own space in Emeryville, CA in August 2013.
This facility provides plenty of space between offices and the lab, an inspiring view of the San Francisco Bay and Bay Bridge, and a perfect environment
for Nano Precision Medical to grow as it continues making progress.
From 2012 to 2019, NPM chose to focus its efforts on research for manufacturing processes and formulation design for a GLP-1 agonist product targeting Type II Diabetes.
In 2019, Nano Precision Medical was excited to demonstrate a commercially attractive human product (in animals), resulting in a shift in focus to advancing NPM-119 towards clinical trials.
Based on the founders’ experience at the UC and its location in the heart of the San Francisco Bay Area, Nano Precision Medical
maintains a culture of creativity, energy, and integrity, while relentlessly advancing its technology and products. By combining
the flexibility and camaraderie of a tech startup with the precision and quality of a pharmaceutical company, Nano Precision Medical
has set its course to make a difference.